The binding of AZIN1 inhibits antizyme-1-mediated binding and degradation of the ornithine decarboxylase (ODC) and cyclin D1 (CCND1) oncoproteins, contributing to cancer initiation and progression, and controlling the proliferative and invasive abilities of cells. The gene discussed is ODC1; the disease is cancer.